Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
100 hedge funds and large institutions have $191M invested in Aratana Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 41 increasing their positions, 22 reducing their positions, and 11 closing their positions.
613% more call options, than puts
Call options by funds: $114K | Put options by funds: $16K
86% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 22
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
14% more capital invested
Capital invested by funds: $167M → $191M (+$24.1M)
5% more funds holding
Funds holding: 95 → 100 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAI
General American Investors
New York
|
+$2.65M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.66M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$1.52M |
| 4 |
Renaissance Technologies
New York
|
+$1.44M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$7.56M |
| 2 |
Millennium Management
New York
|
-$2.01M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
-$1.1M |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$949K |
| 5 |
D.E. Shaw & Co
New York
|
-$874K |
PETX Hedge Fund Activity: Q2 2016 in Review
100 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q2 2016, worth a combined $191M — up 14% from $167M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PETX positions and 11 closed out — a net gain of 5 holders — while 41 added to existing stakes and 22 trimmed.
The largest buyer was General American Investors, opening a new position worth an estimated $2.65M. The largest seller was Jennison Associates, cutting an estimated $7.56M.
- 100 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q2 2016, up from 95 in Q1 2016.
- Funds reported $191M of Aratana Therapeutics, Inc. stock for Q2 2016, up 14% quarter-over-quarter.
- 16 funds opened new Aratana Therapeutics, Inc. positions in Q2 2016 and 11 closed out, a net change of +5 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q2 2016 was General American Investors, an estimated $2.65M added.
- The largest Aratana Therapeutics, Inc. seller in Q2 2016 was Jennison Associates, an estimated $7.56M sold.
Based on aggregated 13F filings for Q2 2016.